诺瓦瓦克斯医药 2026年季度报告

Form10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March31, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to . Commission File No.000-26770NOVAVAX,INC.(Exact name of registrant as specified in its charter) (240)268-2000 (Registrant's telephone number, including area code) N/A(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the Registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Actof 1934 during the preceding 12months (or for such shorter period that the Registrant was required to file such reports), and (2)has been subject tosuch filing requirements for the past 90days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required tosubmit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act. Indicate by check mark whether the Registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No The number of shares outstanding of the Registrant's Common Stock, $0.01 par value, was 164,438,119 as of April30, 2026. NOVAVAX, INC.TABLE OF CONTENTS PART I. FINANCIAL INFORMATION1Item 1.Consolidated Financial Statements1Unaudited Consolidated Statements of Operations and Unaudited Consolidated Statements of ComprehensiveIncome (Loss) for the three months endedMarch 31, 2026 and 20252Consolidated Balance Sheets as ofMarch 31, 2026(unaudited) and December 31, 20253Unaudited Consolidated Statements of Changes in Stockholders’ Deficit for the three months endedMarch 31,2026 and 20254Unaudited Consolidated Statements of Cash Flows for the three months endedMarch 31, 2026 and 20255Notes to the Consolidated Financial Statements (unaudited)6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures about Market Risk38Item 4.Controls and Procedures38PART II. OTHER INFORMATION39Item 1.Legal Proceedings39Item 1A.Risk Factors39Item 5Other Information39Item 6.Exhibits40SIGNATURES41 PARTI. FINANCIAL INFORMATION Item1.Financial Statements NOVAVAX,INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share information)(unaudited) NOVAVAX,INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited) NOVAVAX,INC.NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTSMarch31, 2026(unaudited)Note1– Organization and Business Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, the “Company”) tackles some of the world’smost pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M™adjuvant and protein-based nanoparticles. The Company’s corporate growth strategy is designed to deliver value via three key strategic pillars: partnering itstechnology, capital-efficient R&D innovation, and a lean and efficient operating model supporting our efforts. This includesmaximizing the impact of its cutting-edge technology through existing partnerships for commercial marketed products (Nuvaxovid,R21/Matrix-M™), and by forging new partnerships for its Matrix technology and research and development (R&D) assets. All references to “Nuvaxovid” or “COVID-19 Vaccine” refer to the Company’s Nuvaxovid™ COVID-19 vaccine; allreferences to "JN.1 COVID-19 Vaccine" refer to the Company’s Nuvaxovid™ COVID-19 Vaccine for the 2025-2026 vaccinationseason.TM Currently, the Company significantly depends on its supply agreement with Serum Institute of India Pvt. Ltd. (“SII”) and itssubsidiary, Serum Life Sciences Limited (“SLS” and together with SII, “Serum”), for co-formulation, filling, and finishing of itsCOVID-19 Vaccine. Note2– Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally acceptedaccounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form10-Q a